Overview

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Status:
Active, not recruiting

Trial end date:
2022-07-30

Target enrollment:

Participant gender:

Summary

Phase 3/4, single arm, open-label study to evaluate PK, safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects < 12 years of age.

Phase:

Phase 3

Details

Lead Sponsor:

Aptevo Therapeutics
Medexus Pharma, Inc.